slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,557
Current window 43,171-43,200
Pages 2,019
Rows per page 30
Component
43,171-43,200 of 60,557
18
The slide uses a waterfall-style comparison for Revenue and COGS to emphasize the year-over-year decline.Eos Energy | Results Presentation Deck | 19 slides · Eos Energy Enterprises
Conference presentation Investor relations Beat · Action1 hit
19
The slide uses a green-themed sidebar for upcoming events and a structured table for KPI performance.Eos Energy | Results Presentation Deck | 19 slides · Eos Energy Enterprises
Conference presentation Investor relations Beat · Action1 hit
04
The slide uses a Gantt-style visualization for drug development stages.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Loop · Golden Circle1 hit
06
Includes specific financial breakdown of deal value and R&D funding obligations.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Solution1 hit
20
Includes before/after clinical photos and a comparative table against Mogamulizumab.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Traction1 hit
25
Includes a specific callout for a Blackbox warning on existing competitors.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
37
The slide provides a snapshot of the company's financial health as of late 2023.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
05
The table uses a heatmap-style color coding where red indicates existing targeted therapy markets and teal indicates blue ocean opportunities.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Introduction to Erasca and RAS/MAPK pathwayLoop · Logic Chain1 hit
07
The slide uses a Gantt-style visualization for clinical trial progress.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needsLoop · Logic Chain1 hit
09
The slide uses a matrix structure to map indications to benchmarks, specific drug regimens, and trial names, with a footer detailing active clinical trial collaboration and supply agreements (CTCSAs).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needsLoop · Logic Chain1 hit
11
The slide combines a biological pathway diagram (left) with a quantitative market sizing table (right).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needs1 hit
12
The kinome tree is a standard visualization for kinase selectivity.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needs1 hit
13
The slide combines a biological pathway diagram with a clinical trial summary table to demonstrate proof of concept.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needs1 hit
15
The slide highlights the poor efficacy of current SOC and suggests binimetinib as a superior alternative.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needsLoop · Cost Of Inaction1 hit
16
Waterfall plot shows individual patient responses; table compares efficacy metrics against Dacarbazine and Binimetinib.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical dataLoop · Cost Of Inaction1 hit
19
The slide uses a summary calculation (13/39 = 33.3% ORR) to aggregate results across two different clinical phases.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical dataLoop · Cost Of Inaction1 hit
24
The slide uses a biological signaling pathway map to justify combination therapy strategy.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
25
The diagram shows the RAS/MAPK signaling pathway. The table provides a breakdown of patient populations for specific indications.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
30
Data cut 23MAR2023. TRAE = Treatment-related Adverse Event. EC = Encorafenib + Cetuximab.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
35
The table compares 'ALL' vs 'Gr >= 3' adverse events for different dosing regimens.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
36
The diagram shows the EGFR signaling pathway and the inhibitory effect of ERAS-801.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
37
The slide uses a stacked bar chart to show mutation incidence and a comparison table to contrast clinical outcomes across different indications.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
38
The slide uses Western blot data to demonstrate potency and a table to demonstrate pharmacokinetic superiority.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
42
The slide uses a table format to communicate a product roadmap for clinical development.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
48
The slide uses western blot data to demonstrate the superiority of ERAS-007 in a specific biological pathway context.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
49
Includes RECIST 1.1 criteria reference and patient progression note.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
52
Data from HERKULES-1 study, cutoff 23 May 2022.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
53
The slide uses a line chart to show concentration over time and a table to summarize key PK metrics (Cmax, Cmin, T>IC90, T<IC50) for five different dosing regimens.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
22
Financial data presented in thousands of dollars.Etsy | Investor Presentation Deck | 26 slides · Etsy
Pitch deck Investor relations Beat · Financials1 hit
23
Includes Q3 2023 financial results.Etsy | Investor Presentation Deck | 26 slides · Etsy
Pitch deck Investor relations Beat · Financials1 hit